A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model

NCT03231969 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

121

Enrollment

INDUSTRY

Sponsor class

Conditions

Allergic Conjunctivitis

Interventions

DRUG: Bilastine 0.2%
DRUG: Bilastine 0.4%
DRUG: Bilastine 0.6%
DRUG: Bilastine 0%

Sponsor

Faes Farma, S.A.

Collaborators

[object Object]